Faisal Khurshid
Stock Analyst at Leerink Partners
(4.52)
# 278
Out of 5,131 analysts
30
Total ratings
56.52%
Success rate
38.87%
Average return
Main Sectors:
Stocks Rated by Faisal Khurshid
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Outperform | $70 → $118 | $82.34 | +43.31% | 3 | Dec 9, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Outperform | $13 → $16 | $10.40 | +53.85% | 2 | Nov 20, 2025 | |
| ABCL AbCellera Biologics | Downgrades: Market Perform | $4 | $3.10 | +29.03% | 2 | Nov 7, 2025 | |
| GLPG Galapagos NV | Upgrades: Outperform | $29 → $40 | $33.90 | +17.99% | 2 | Oct 21, 2025 | |
| CTNM Contineum Therapeutics | Initiates: Outperform | $20 | $14.49 | +38.03% | 1 | Sep 25, 2025 | |
| ATYR aTyr Pharma | Downgrades: Market Perform | $1 | $0.89 | +11.87% | 2 | Sep 15, 2025 | |
| PTGX Protagonist Therapeutics | Initiates: Outperform | $73 | $81.49 | -10.42% | 1 | Sep 12, 2025 | |
| STTK Shattuck Labs | Maintains: Outperform | $4 → $2 | $3.86 | -48.19% | 2 | Aug 14, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Outperform | $88 → $102 | $98.07 | +4.01% | 2 | Jul 10, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Perform | $3 → $1 | $4.50 | -77.78% | 2 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $36.63 | +22.85% | 1 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $16 | $15.60 | +2.56% | 1 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $33 → $2 | $1.11 | +80.18% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $77.36 | +3.41% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $6.08 | +146.71% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $45 | $17.61 | +155.54% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.65 | +324.24% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $5.66 | +41.34% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $5 | $0.91 | +447.95% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $11 | $2.78 | +295.68% | 1 | Mar 21, 2023 |
Kymera Therapeutics
Dec 9, 2025
Maintains: Outperform
Price Target: $70 → $118
Current: $82.34
Upside: +43.31%
Trevi Therapeutics
Nov 20, 2025
Maintains: Outperform
Price Target: $13 → $16
Current: $10.40
Upside: +53.85%
AbCellera Biologics
Nov 7, 2025
Downgrades: Market Perform
Price Target: $4
Current: $3.10
Upside: +29.03%
Galapagos NV
Oct 21, 2025
Upgrades: Outperform
Price Target: $29 → $40
Current: $33.90
Upside: +17.99%
Contineum Therapeutics
Sep 25, 2025
Initiates: Outperform
Price Target: $20
Current: $14.49
Upside: +38.03%
aTyr Pharma
Sep 15, 2025
Downgrades: Market Perform
Price Target: $1
Current: $0.89
Upside: +11.87%
Protagonist Therapeutics
Sep 12, 2025
Initiates: Outperform
Price Target: $73
Current: $81.49
Upside: -10.42%
Shattuck Labs
Aug 14, 2025
Maintains: Outperform
Price Target: $4 → $2
Current: $3.86
Upside: -48.19%
Rhythm Pharmaceuticals
Jul 10, 2025
Maintains: Outperform
Price Target: $88 → $102
Current: $98.07
Upside: +4.01%
Ironwood Pharmaceuticals
Apr 14, 2025
Maintains: Market Perform
Price Target: $3 → $1
Current: $4.50
Upside: -77.78%
Apr 8, 2025
Initiates: Outperform
Price Target: $45
Current: $36.63
Upside: +22.85%
Mar 17, 2025
Initiates: Market Perform
Price Target: $16
Current: $15.60
Upside: +2.56%
Mar 3, 2025
Downgrades: Market Perform
Price Target: $33 → $2
Current: $1.11
Upside: +80.18%
Dec 11, 2024
Initiates: Outperform
Price Target: $80
Current: $77.36
Upside: +3.41%
Nov 4, 2024
Initiates: Outperform
Price Target: $15
Current: $6.08
Upside: +146.71%
Sep 9, 2024
Assumes: Outperform
Price Target: $45
Current: $17.61
Upside: +155.54%
Sep 9, 2024
Initiates: Outperform
Price Target: $7
Current: $1.65
Upside: +324.24%
Sep 9, 2024
Assumes: Outperform
Price Target: $8
Current: $5.66
Upside: +41.34%
Sep 9, 2024
Assumes: Outperform
Price Target: $5
Current: $0.91
Upside: +447.95%
Mar 21, 2023
Initiates: Outperform
Price Target: $11
Current: $2.78
Upside: +295.68%